Background Despite recent advances in treatment strategies, it is still difficult to cure patients
with hepatocellular carcinoma (HCC). Sorafenib is the only approved multiple kinase …

We determined the mitogen-activated protein kinase (MAPK) gene expression profile of
acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed …

Purpose Although sorafenib enhances overall survival, sorafenib resistance has been
reported to be a significant limiting factor for improved prognosis in patients with …

Purpose Sorafenib, a multikinase inhibitor, is the standard therapy for patients with
advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …

Hepatocellular carcinoma (HCC) is one of the most common potentially lethal human
malignancies worldwide. Sorafenib, a tyrosine kinase inhibitor, was recently approved by …

Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …

Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and
angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the …

Purpose: The purpose of this study was to determine the impact of sorafenib on
PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating …

Sorafenib, a multi‐kinase inhibitor, is the only standard clinical drug for patients with
advanced hepatocellular carcinoma (HCC); however, development of sorafenib resistance …